AbbVie's Alzheimer's Efforts Voyage Into AAV-Targeted Tau Antibodies
Collaboration between Voyager and AbbVie will attempt to produce a single-administration gene therapy targeting tau protein, using adeno-associated vector technology to pass the blood-brain barrier.
You may also be interested in...
While it works on merging with Allergan, AbbVie is tracking biosimilar sales erosion to Humira, the promising launch of Skyrizi and the growth of Imbruvica and Venclexta. It is terminating a Phase II study of a tau-targeting antibody and worried about aspects of the Senate drug pricing bill.
AbbVie has added Mission Therapeutics to its preclinical partnership roster with a neurology deal to develop DUB inhibitors in Alzheimer’s and Parkinson’s disease.
The pharma and the Google spinout focused on aging are adding $1bn in funding to their 2014 collaboration, which has yielded more than two dozen preclinical candidates so far.